Status:
COMPLETED
IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency
Lead Sponsor:
Emory University
Conditions:
T-Cell Immune Deficiency Diseases
Severe Combined Immunodeficiency
Eligibility:
All Genders
Phase:
PHASE1
PHASE2
Brief Summary
This is a multi-institution, single arm, non-randomized pilot study coordinated by the Pediatric Blood and Marrow Transplant Consortium. Eligible patients will have severe combined immunodeficiency sy...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with the following primary severe T-cell immune deficiency diseases and donor types will be eligible for this pilot trial:
- Immunophenotype: SCIDs with decreasing T, any B, increasing natural killer (NK) with partial matched family member, unrelated donor marrow or cord blood, with or without T depletion; OR
- Combined immunodeficiency disease (CID), including Wiskott-Aldrich and severe DiGeorge's with any donor type.
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00228852
End Date
November 1 2006
Last Update
June 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322